rev: July 10, 2003


Return (human cytokine index)

Human Cytokine/Growth Factor/Chemokines Sample Spec sheets (subject to change without notice):

Recombinant Human sFGFR-4/Fc Chimera  (see also sFGFR-2 & sFGFR-1 & sFGFR-3)
Recombinant Human sFGFR-4/Fc Chimera

Cat#RDI-SFC021  $438.00/50ug

Description: Recombinant human soluble FGFR-4 was fused with the Fc part of human IgG1. Human recombinant soluble FGFR-4/Fc is a disulfide-linked heterodimeric protein. The reduced form of human FGFR-4/ Fc is a monomer with a calculated molecular mass of approximately 65 kDa. As a result of glycosylation, the recombinant protein has a mass of 80-85 kDa. Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorgenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1 -4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1 - 3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the a isoform, or only IgII and IgIII, referred to as the b isoform. Only the a isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1 - 3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R1 - 3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are under investigation.

Source:                    Insect cells

Molecular Weight:  170 kDa

Subunit:                   glycosylated dimmer

Purity:                     > 90%, by SDS-PAGE and visualised by silver stain

Endotoxin level:     < 0.1 ng per ug of sFGFR-4

Stabilizer:               none

Buffer:                     none

Formulation:           lyophilized

Biological Activity: Determined by its ability to inhibit human FGF basic-dependent proliferation on HUVE cells. The ED50 for this effect is typically at 15 - 30 ng/ml.

Reconstitution: The lyophilized sFGFR-4/Fc is soluble in water and most aqueous buffers. The lyophilized sFGFR-4/Fc should be reconstituted in sterile water or PBS, allowed ot set at leats 30 minutes, then diluted into PBS or medium to a concentration not lower than 50 µg/ml.

Stability: Lyophilized samples are stable for greater than six months at -20°C to -70°C. Reconstituted sFGFR-4/ Fc should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles!

Usage: sFGFR-4/Fc is offered for research use. Not for drug use. Not for human use!

Literature: [Ezzat et al., Biochem Biophys Res Commun. 287:60, 2001; Takaishi et al., Biochem Biophys Res Commun. 267:658, 2000]

For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

RDI Divison of researchd Industries Intl

San Jose, 95123 CA Snell ave 658


or (800) 370-2222


Return (human cytokine index)

Ordering terms

all rights reserved by any/all copyright holders?